Literature DB >> 24084059

Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia.

Mari C de la Torre1, Ignasi Bolíbar, Montse Vendrell, Javier de Gracia, Ester Vendrell, M José Rodrigo, Xavier Boquet, Pablo Torrebadella, Joan-Carles Yébenes, Mateu Serra-Prat, Jordi Rello, Antoni Torres, Jordi Almirall.   

Abstract

BACKGROUND: A population-based case-control study was designed to assess changes of serum levels of immunoglobulins and IgG subclasses between infected and convalescent phase in community-acquired pneumonia (CAP).
METHODS: Over a 2-year period, all subjects who were >14 years of age living in the Maresme region (Barcelona, Spain) diagnosed of CAP were registered. Controls were healthy subjects selected from the municipal census. Prognostic factors were assessed and serum levels of total IgG, IgA, IgM, and IgG subclasses were measured at diagnosis and 1 month later (cases).
RESULTS: We studied 171 patients with CAP and 90 controls. All immunoglobulins were significantly lower in cases than in controls. At diagnosis, 42.7% of cases showed low levels of some immunologic parameter, mainly total IgG and IgG2. Low immunoglobulin levels at diagnosis were more frequent in patients requiring in-patient care and in those with pneumonia of other etiology than Streptococcus pneumoniae. In the convalescent phase, 26 (23.6%) patients normalized immunological levels. In 27 (24.5%) cases, some parameter with low levels persisted especially in patients with etiology of CAP other than S. pneumoniae.
CONCLUSIONS: Low serum levels of immunoglobulins particularly total IgG and IgG2 were a common finding in patients with CAP compared to healthy controls. Low immunoglobulin levels may be related to CAP prognosis and persisted in the convalescent phase in one-fourth of cases.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Community-acquired pneumonia; IgG; IgG subclasses; Immunoglobulins; Prognosis

Mesh:

Substances:

Year:  2013        PMID: 24084059     DOI: 10.1016/j.rmed.2013.09.005

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  9 in total

Review 1.  The role of genetics and antibodies in sepsis.

Authors:  Evangelos J Giamarellos-Bourboulis; Steven M Opal
Journal:  Ann Transl Med       Date:  2016-09

2.  Serum Immunoglobulins, Pneumonia Risk, and Lung Function in Middle-Aged and Older Individuals: A Population-Based Cohort Study.

Authors:  Samer R Khan; Anna Vanoverschelde; Lies Lahousse; Robin P Peeters; P Martin van Hagen; Guy Brusselle; Layal Chaker; Virgil A S H Dalm
Journal:  Front Immunol       Date:  2022-06-02       Impact factor: 8.786

3.  Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study).

Authors:  Tobias Welte; R Phillip Dellinger; Henning Ebelt; Miguel Ferrer; Steven M Opal; Mervyn Singer; Jean-Louis Vincent; Karl Werdan; Ignacio Martin-Loeches; Jordi Almirall; Antonio Artigas; Jose Ignacio Ayestarán; Sebastian Nuding; Ricard Ferrer; Gonzalo Sirgo Rodríguez; Manu Shankar-Hari; Francisco Álvarez-Lerma; Reimer Riessen; Josep-Maria Sirvent; Stefan Kluge; Kai Zacharowski; Juan Bonastre Mora; Harald Lapp; Gabriele Wöbker; Ute Achtzehn; David Brealey; Axel Kempa; Miguel Sánchez García; Jörg Brederlau; Matthias Kochanek; Henrik Peer Reschreiter; Matthew P Wise; Bernd H Belohradsky; Iris Bobenhausen; Benjamin Dälken; Patrick Dubovy; Patrick Langohr; Monika Mayer; Jörg Schüttrumpf; Andrea Wartenberg-Demand; Ulrike Wippermann; Daniele Wolf; Antoni Torres
Journal:  Intensive Care Med       Date:  2018-04-09       Impact factor: 17.440

Review 4.  Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group.

Authors:  Mathias W Pletz; Andreas Vestergaard Jensen; Christina Bahrs; Claudia Davenport; Jan Rupp; Martin Witzenrath; Grit Barten-Neiner; Martin Kolditz; Sabine Dettmer; James D Chalmers; Daiana Stolz; Norbert Suttorp; Stefano Aliberti; Wolfgang M Kuebler; Gernot Rohde
Journal:  Respir Res       Date:  2022-09-10

5.  Serum levels of immunoglobulins and severity of community-acquired pneumonia.

Authors:  Mari C de la Torre; Pere Torán; Mateu Serra-Prat; Elisabet Palomera; Estel Güell; Ester Vendrell; Joan Carles Yébenes; Antoni Torres; Jordi Almirall
Journal:  BMJ Open Respir Res       Date:  2016-11-28

Review 6.  New aspects in the management of pneumonia.

Authors:  Elena Prina; Adrian Ceccato; Antoni Torres
Journal:  Crit Care       Date:  2016-10-01       Impact factor: 9.097

7.  Low Levels of Immunoglobulins and Mannose-Binding Lectin Are Not Associated With Etiology, Severity, or Outcome in Community-Acquired Pneumonia.

Authors:  William W Siljan; Jan C Holter; Ståle H Nymo; Einar Husebye; Thor Ueland; Lillemor Skattum; Vidar Bosnes; Peter Garred; Stig S Frøland; Tom E Mollnes; Pål Aukrust; Lars Heggelund
Journal:  Open Forum Infect Dis       Date:  2018-01-05       Impact factor: 3.835

Review 8.  Nonantibiotic Adjunctive Therapies for Community-Acquired Pneumonia (Corticosteroids and Beyond): Where Are We with Them?

Authors:  Oriol Sibila; Ana Rodrigo-Troyano; Antoni Torres
Journal:  Semin Respir Crit Care Med       Date:  2016-12-13       Impact factor: 3.119

9.  Immunoglobulins concentration and B cell counts as severity markers in adult community-acquired pneumonia: Cross sectional study.

Authors:  Vivian Luchsinger; Luis Lizama; María Luisa Garmendia; Fabián Tempio; Mauricio Ruiz; Rolando Pizarro; Patricio Rossi; Lucía Huenchur; Cristian Moreno; Mercedes López; Sandra Ampuero; Carmen Larrañaga; Luis Fidel Avendaño
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.